Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and …

Background LY-CoV555, a neutralizing monoclonal antibody, has been associated with a
decrease in viral load and the frequency of hospitalizations or emergency department visits …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …

Abstract Background Coronavirus disease 2019 (COVID-19) is a global pandemic with no
licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal …

To assess the clinical efficacy and safety of neutralizing monoclonal antibodies (mABs) for
outpatients with coronavirus disease 2019 (COVID‐19). PubMed, Embase, Web of Science …

Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Background: There are no studies providing head-to-head comparison across SARS-CoV-2
vaccines. Therefore, we compared the efficacy of candidate vaccines in inducing …